MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from rights
offering, net
$5,392K
Proceeds from long-term
debt
$2,478K
Cash for exercise of
warrants, net
$1,439K
Net cash provided by
financing activities
$9,309K
Effect of exchange
rates on cash
$1,490K
Net change in cash,
cash equivalents,...
-$1,993K
Canceled cashflow
$10,799K
Stock-based compensation
$2,765K
Prepaid expenses and
other current assets
-$1,791K
Depreciation and
amortization
$1,234K
Amortization of debt discount
$820K
Loss on abandoned
patents
$559K
Grants and accounts
receivable
-$423K
Amortization of patents
$262K
Write off of inventory
$253K
Amortization of right-of-use
asset
$135K
Write off of fixed
assets
$104K
Bad debt expense
$40K
Other assets
-$2K
Disposal of property and
equipment
$76K
Net cash used in
operating activities
-$12,377K
Canceled cashflow
$8,388K
Net cash used in
investing activities
-$415K
Canceled cashflow
$76K
Foreign currency
transaction (gains) losses
$9,321K
Net loss
-$8,198K
Inventories
$2,540K
Accounts payable and
accrued expenses
-$706K
Patent costs
$327K
Purchases of property and
equipment
$164K
Back
Back
Cash Flow
source: myfinsight.com
Cytosorbents Corp (CTSO)
Cytosorbents Corp (CTSO)